About the Company
lixte biotechnology holdings, inc. (lixte) is a clinical-stage public (lixt) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. the current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and dna damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. the phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. the lead compound lb-100 is in phase i trial and has the potential to be first-in-class. the deacetylase in
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LIXT News
Why Lixte Biotechnology Stock Is Soaring
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares are trading higher Wednesday after the company announced the ...
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE ...
Biotech Steals The Show Following Pre-Clinical Data Announcement
Real-time index price for S&P 500 Index (INX), along with buy or sell indicators, analysis, charts, historical performance, ...
Lixte Biotechnology gets grant for in vivo delivery of endothall to cancer cells
Discover a groundbreaking patent by Lixte Biotechnology for in vivo delivery of endothall to cancer cells, focusing on brain cancer treatment. Explore new possibilities in cancer therapy today!
Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also ...
Lixte Biotechnology Shares Rise 51% After Positive Data for LB-100 Cancer Treatment
By Chris Wack Lixte Biotechnology Holdings shares were up 51% at $3.41 after the company said pre-clinical data showed that its lead clinical ...
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers --PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) ...
LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q4 2023
The post LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q4 2023 appeared first on InvestorPlace. Lixte Biotechnology Holdings NewsMORE Related Stocks Indices Commodities Currencies ...
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.22%
U.S. stocks were higher after the close on Wednesday, as gains in the Utilities, Basic Materials and Telecoms sectors led ...
Gold Moves Higher; Velo3D Shares Plummet
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index gaining over 300 points on Wednesday. The Dow traded up 0.78% to 39,589.55 while the NASDAQ fell 0.02% to 16,312.74 ...
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary ...
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Another one of the Street’s favorite biotech stocks is Immunovant (NASDAQ: IMVT ), where recent weakness is an opportunity.
Loading the latest forecasts...